Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
Last trade$34.12
Day change-$1.32 (-3.72%)
Day range$34.00 – $35.95
Volume221,840
Market cap$1.63B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.63B
Price / earnings
36.5×
Price / book
1.24×
Price / sales
1.31×
EV / sales
1.19×
EV / EBITDA
10.58×
Profitability
Earnings per share
$0.97
Return on assets
2.17%
Return on equity
3.39%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.13×
Current ratio
1.66×
Quick ratio
1.45×
Cash ratio
0.66×
Cash flow
Price / cash flow
8.75×
Price / free cash flow
11.18×
Free cash flow
$145.77M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for OMCL, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$307.85M
$312.21M
$309.88M
$313.98M
$310.63M
$290.56M
$269.67M
$306.88M
Cost of revenue
$170.03M
$159.27M
$169.52M
$183.66M
$176.13M
$162.88M
$158.73M
$165.12M
Gross profit
$137.83M
$152.94M
$140.36M
$130.33M
$134.5M
$127.68M
$110.94M
$141.76M
Selling, general and administrative
$100.54M
$100.19M
$101.99M
$107.36M
$102.24M
$97.99M
$102.03M
$103.33M
Research and development
$22.35M
$20.3M
$21.52M
$22.55M
$24.02M
$21.57M
$20.53M
$26.04M
Total operating expenses
$122.89M
$120.49M
$123.51M
$129.91M
$126.26M
$119.56M
$122.56M
$129.37M
Operating income
$14.93M
$32.45M
$16.85M
$415K
$8.24M
$8.12M
-$11.62M
$12.4M
Interest expense
$0
$432K
$51K
$0
$0
$542K
$2.09M
$0
Income before taxes
$15.8M
$33.83M
$16.91M
$699K
$9.7M
$10.45M
-$9.53M
$23.6M
Income taxes
$4.76M
$9.54M
$5.55M
$2.73M
$4.24M
$4.81M
-$2.51M
$7.76M
Net income
$11.04M
$24.29M
$11.36M
-$2.03M
$5.46M
$5.64M
-$7.02M
$15.84M
Net income attributable to common shareholders
$11.04M
$24.29M
$11.36M
-$2.03M
$5.46M
$5.64M
-$7.02M
$15.84M
EBITDA
$33.34M
$51.28M
$35.43M
$20.23M
$27.65M
$27.71M
$8.38M
$32.36M
Basic earnings per share
$0.24
$0.53
$0.25
-$0.05
$0.12
$0.12
-$0.15
$0.34
Diluted earnings per share
$0.24
$0.52
$0.25
-$0.04
$0.12
$0.12
-$0.15
$0.34
Recent news
Company coverage with links to the original publishers.
The article identifies four stocks that qualify as attractive PEG-driven value investment picks based on discounted valuations combined with strong earnings growth prospects. Using screening criteria including PEG ratio, P/E ratio, Zacks Rank, and Value Score, the selected stocks are positioned to offer upside potential for value investors seeking to avoid value traps.
Following a strong market rally driven by falling oil prices and renewed technology buying interest, Zacks highlights four undervalued stocks with attractive Price-to-Cash Flow ratios: Avnet, Omnicell, Hewlett Packard Enterprise, and Lifetime Brands. These fundamentally strong companies with stable earnings and healthy cash flows are positioned to benefit from improved investor sentiment.
Zacks highlights three stocks with recent broker rating upgrades as attractive investment opportunities. Cinemark Holdings expects 164.4% earnings growth in 2026, Diamondback Energy projects 68.8% earnings growth, and Omnicell anticipates 47.5% earnings growth. All three stocks hold Zacks Rank #1 ratings and have received upward broker revisions over the past four weeks.
Despite market headwinds from AI spending concerns, elevated Treasury yields, and tariff uncertainty, three stocks have received significant broker rating upgrades: Cinemark Holdings (CNK) with 7.1% upgrade and 164.4% projected 2026 earnings growth, Diamondback Energy (FANG) with 3% upgrade and 68.8% projected earnings growth, and Omnicell (OMCL) with 11.1% upgrade and 47.5% projected earnings growth. All three carry Zacks Rank #1 ratings.
U.S. stock markets surged with the Dow gaining 2.15%, S&P 500 up 2.35%, and Nasdaq climbing 2.74%, driven by falling oil prices easing inflation concerns and renewed technology buying. The article highlights four value stocks with attractive Price-to-Cash Flow ratios as potential investment opportunities.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.